S&P Futures
4,003.00 -16.75 (-0.42%) Dow Futures
32,055.00 -65.00 (-0.20%) Nasdaq Futures
12,299.25 -83.50 (-0.67%) Russell 2000 Futures
1,781.60 -7.90 (-0.44%) Crude Oil
109.12 -1.37 (-1.24%) Gold
1,795.60 -12.60 (-0.70%)
Adial Pharmaceuticals, Inc. (ADIL)
Chart Events
Performance Outlook
| Previous Close | 1.2900 |
| Open | 1.3000 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1200 |
| Day's Range | 1.2500 - 1.3256 |
| 52 Week Range | 1.1400 - 5.0800 |
| Volume | |
| Avg. Volume | 114,591 |
| Market Cap | 30.36M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0450 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADIL
Related Research
- Adial Pharmaceuticals, IncMarket Update: COST, TGNA, ITRI, LLY, ANTM, WWW, AGNC, GNRC, LTHM, NRZStocks rallied on Friday morning, paring some of their recent sharp losses. However, the major indices were still on track for their sixth straight weekly decline amid continued concerns about inflation and the Fed's ability to control it. In an NPR interview on Thursday, Fed Chair Jerome Powell reiterated that the central bank would likely raise interest rates by 50 basis points at each of its next two meetings, but that it was 'prepared to do more' if the data warranted. The Dow rose 1.4%, the S&P 2.1%, and the Nasdaq 3.6%. Crude oil rose $4 to $110 per barrel, while gold traded near $1813 per ounce.RatingFair ValueEconomic Moat3 days agoArgus Research
- GlobeNewswire
Maravai LifeSciences Reports First Quarter 2022 Financial Results
Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS GuidanceSAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2022, together with other business updates. Highlights include: Record quarterly revenue of $244.3 million, an increase of 65% over the prior year;Nucl
- GlobeNewswire
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major unmet medical needs, has entered into a research collaboration agreement with the University of California San Diego (UC San Diego), a leading education and research university, and Dr. Peter Ernst, DVM, PhD, Professor of Pathology and an expert
- Zacks
5 Winning Stocks Backed by the Overlooked Rising P/E Strategy
Want to try an out-of-the-box approach? Tap five stocks (GIII, PPC, TAL, ADIL and CHS) with increasing P/E ratios.
